A study to assess effect of rituximab and ocrelizumab therapy in anti-HBC positive patients with multiple sclerosis or neuromyelitis optica spectrum disorders is not associated with HBV reactivation
Latest Information Update: 20 Oct 2020
Price :
$35 *
At a glance
- Drugs Ocrelizumab (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis; Neuromyelitis optica
- Focus Pharmacodynamics; Therapeutic Use
- 20 Oct 2020 New trial record
- 29 Aug 2020 Results presented at The International Liver Congress 2020